相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Tatsuhiro Shibata et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
S. Soverini et al.
LEUKEMIA (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
W-C Chou et al.
LEUKEMIA (2011)
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Susanne Schnittger et al.
BLOOD (2010)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
Claire L. Green et al.
BLOOD (2010)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
Felicitas Thol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
A. Tefferi et al.
LEUKEMIA (2010)
Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)
A. Pardanani et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
A. Pardanani et al.
LEUKEMIA (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
O. Kosmider et al.
LEUKEMIA (2010)
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia
D. Caramazza et al.
LEUKEMIA (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
A. Tefferi et al.
LEUKEMIA (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Risk factors for leukemic transformation in patients with primary myelofibrosis
Jocelin Huang et al.
CANCER (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - An international internet-based survey of 1179 MPD patients
Ruben A. Mesa et al.
CANCER (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)